Effectiveness of Micronutrient Powders (MNP) in women and children by unknown
REVIEW Open Access
Effectiveness of Micronutrient Powders (MNP)
in women and children
Rehana A Salam1, Ceilidh MacPhail2, Jai K Das1, Zulfiqar A Bhutta1,3*
Abstract
Introduction: More than 3.5 million women and children under five die each year in poor countries due to
underlying undernutrition. Many of these are associated with concomitant micronutrient deficiencies. In the last
decade point of use or home fortification has emerged to tackle the widespread micronutrient deficiencies. We in
this review have estimated the effect of Micronutrient Powders (MNPs) on the health outcomes of women and
children.
Methods: We systematically reviewed literature published up to November 2012 to identify studies describing the
effectiveness of MNPs. We used a standardized abstraction and grading format to estimate the effect of MNPs by
applying the standard Child Health Epidemiology Reference Group (CHERG) rules.
Results: We included 17 studies in this review. MNPs significantly reduced the prevalence of anemia by 34% (RR:
0.66, 95% CI: 0.57-0.77), iron deficiency anemia by 57% (RR: 0.43, 95% CI: 0.35-0.52) and retinol deficiency by 21%
(RR: 0.79, 95% CI: 0.64, 0.98). It also significantly improved the hemoglobin levels (SMD: 0.98, 95% CI: 0.55-1.40).
While there were no statistically significant impacts observed for serum ferritin and zinc deficiency. Our analysis
shows no impact of MNPs on various anthropometric outcomes including stunting (RR: 0.92, 95% CI: 0.81, 1.04),
wasting (RR: 1.13, 95% CI: 0.91, 1.40), underweight (RR:0.96, 95% CI: 0.83, 1.10), HAZ (SMD: 0.04, 95% CI: -0.13, 0.22),
WAZ (SMD: 0.05, 95% CI: -0.12, 0.23) and WHZ (SMD: 0.04, 95% CI: -0.13, 0.21), although showing favorable trends.
MNPs were found to be associated with significant increase in diarrhea (RR: 1.04, 95% CI: 1.01, 1.06) with non-
significant impacts on fever and URI.
Conclusion: Our analysis of the effect of MNPs in children suggests benefit in improving anemia and hemoglobin
however the lack of impact on growth and evidence of increased diarrhea requires careful consideration before
recommending the intervention for implementing at scale.
Introduction
More than 3.5 million women and children under five
die each year in poor countries due to underlying
undernutrition [1]. An estimated 178 million children
under five are stunted and 55 million children are
wasted [2]. Of these stunted children, 160 million (90%)
live in just 36 countries, representing almost half of the
children in those countries [2] and many of these chil-
dren have concomitant micronutrient deficiencies. Defi-
ciencies in vitamin A, iron, zinc and iodine are the most
prevalent, accounting for 11% of global disease burden
[3]. The World Health Organization (WHO) estimates
that of the roughly two billion people suffering from
micronutrient deficiencies, 85% live in resource poor
settings [4]and these often occur as multiple rather than
single micronutrient deficiencies [5]. The prevalence is
especially high in Southeast Asia and sub-Saharan
Africa.
Iron deficiency is widespread and globally about 1.62
billion people are anemic with the highest prevalence
among preschool children (47%) followed by pregnant
women (42%) [6]. Iodine deficiency (IDD) is a public
health problem in 130 countries and affects 13% of
world’s population [7]. Globally about 740 million peo-
ple are affected by goiter, and over two billions are con-
sidered at risk of IDD. It is estimated that one-third of
the world population live in countries with a high preva-
lence of zinc deficiency. Clinical Vitamin A Deficiency
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(VAD) affects at least 2.80 million preschool children in
over 60 countries, and sub clinical VAD is considered a
problem for at least 251 million that includes school-age
children and pregnant women [8].
Micronutrients play a critical role in cellular and
humoral immune responses, cellular signaling and func-
tion, learning and cognitive functions, work capacity,
reproductive health and even in the evolution of micro-
bial virulence [9,10]. Infants, children and pregnant
women have high demands for vitamins and minerals
because of increased growth and metabolic requirements
and yet their dietary intake often fails to meet these
requirements [3,11]. In children these micronutrient
deficiencies can cause anemia [12], restrict growth [13]
and hamper motor and cognitive development [14] and
also effect the immune function [15]. Under nutrition in
children and women leaves a long term impact on
population health and productivity.
Several strategies have been employed to supplement
micronutrients to women and children [16-19]. These
include nutrition education, dietary modification, food
provision, supplementation and fortification. In the last
decade point of use or home fortification of maternal
and child diets has emerged to tackle the widespread
micronutrient deficiencies. Multiple Micronutrient Pow-
ders (MNPs) or Sprinkles are powdered encapsulated
vitamins and minerals that can be added to prepared
foods with little change to the food’s taste or texture.
MNPs are designed to provide the recommended daily
nutrient intake of 2 or more vitamins and minerals to
their target populations.
Despite the wide body of primary research on MNP
interventions, there are few syntheses of the existing
data. A recent Cochrane review has established that
MNPs appear effective for reducing anemia and iron
deficiency for children under 2 years of age [20]. We in
this review have estimated the effect of these MNPs on
the health of women and children. We have reviewed
the available literature and evaluated the quality of
included studies according to the Child Health Epide-
miology Group (CHERG) adaptation of Grading of
Recommendations, Assessments, Development and Edu-
cation (GRADE) criteria [21].
Methods
We systematically reviewed literature published up to
November 2012 to identify studies describing the effec-
tiveness of MNPs. Following CHERG Systematic Review
Guidelines [21], we searched PubMed, Cochrane
Libraries, Embase, and WHO Regional Databases to
identify all published and unpublished trials. Additional
studies were identified by hand searching references
from included studies. Search terms included combina-
tions of Micronutrient* OR ‘multiple micronutrient” OR
“multi-vitamin” OR “multi-mineral” OR “micronutrient
powder” OR MNP OR sprinkle AND Fortifi* OR “food
fortifi*” OR “point of use” OR “home fortification”. No
language or date restrictions were applied in the
searches.
Inclusion criteria
MNPs were identified as point-of-use powders with two
or more micronutrients in their formulation. Studies
were included that provided MNPs either in the home
or at designated centers, using different multiple micro-
nutrient formulations, with different dosages and dura-
tion. Studies that included supporting interventions
such as nutrition education were included only if the
supporting interventions were given to both the inter-
vention and comparison groups, so that the difference
between the two groups was solely of MNPs. Because of
the unique nature of this intervention and a need to do
a separate analysis specifically for this intervention, we
excluded studies examining the impact of supplementary
food provision, lipid-based supplements, micronutrient
crushable tablets or foodlets, fortified milk or comple-
mentary foods and other fortified foods and beverages
including fortified seasoning powders.
Abstraction, analysis and summary measure
We abstracted data describing study identifiers and con-
text, study design and limitations, intervention specifics
and outcome effects into a standardized abstraction
form for studies that met the final inclusion criteria as
detailed in the CHERG Systematic Review Guidelines
[21]. Outcomes of interest included hematological; ane-
mia, hemoglobin levels, serum micronutrient levels,
anthropometric; stunting, wasting, underweight, weight
for age z-score (WAZ), height for age z- score (HAZ),
weight for height z-score (WHZ), head circumference
and morbidity; diarrhea, upper respiratory infections
(URI), fever and mortality among women and children.
Each study was assessed and graded according to the
CHERG adaptation of the GRADE technique [21].
Quantitative data synthesis
We conducted a meta-analysis for individual studies and
pooled statistics were reported as the relative risk (RR)
for categorical variables and standard mean difference
(SMD) for continuous variables between the experimen-
tal and control groups with 95% confidence intervals
(CI). Mantel–Haenszel pooled RR and corresponding
95% CI were reported or the DerSimonian–Laird pooled
RR and corresponding 95% CI where there was an unex-
plained heterogeneity. All analyses were conducted using
the software Review Manager 5.1. Heterogeneity was
quantified by Chi2 and I2, which can be interpreted as
the percentage of the total variation between studies
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that is attributable to heterogeneity rather than to
chance, a low p-value (less than 0.1) or a large chi-
squared statistic relative to its degree of freedom and I2
values greater than 50% were taken as substantial and
high heterogeneity. In situations of high heterogeneity,
causes were explored by sensitivity analysis and random
effect models were used.
We summarized the evidence by outcome, including
qualitative assessments of study quality and quantitative
measures, according to the standard guidelines. A grade
of “high”, “moderate”, “low” and “very low” was used for
grading the overall evidence indicating the strength of
an effect on specific health outcome according to the
CHERG Rules for Evidence Review [21].
Results
We identified 2556 titles from search conducted in all
databases. After screening titles and abstracts, we
reviewed 26 papers for the identified outcome mea-
sures of interest of which 11 papers investigated either
multiple micronutrient spreads or seasonings and were
excluded from this review and 17 [22-38] studies were
finally selected for inclusion which evaluated the
impact of MNP versus no intervention or control and
reported the outcomes of interest (Figure 1). Most of
the studies were done on children aged 6 months to 6
years of age, while two studies had children up to 11
years of age. All studies were conducted in developing
countries. There were no studies identified which were
on women and met our inclusion criteria. None of the
included studies reported on the outcome of mortality.
Table 1 shows the characteristics of the included
studies.
In Table 2 and 3, we report the quality assessment of
studies by outcomes. All the evidence was of moderate
outcome specific quality. For the hematologic indicators
(Table 2), the findings were based on 15 studies. MNPs
significantly reduced the prevalence of anemia by 34%
(RR: 0.66, 95% CI: 0.57-0.77) (Figure 2), iron deficiency
anemia by 57% (RR: 0.43, 95% CI: 0.35-0.52) and retinol
deficiency by 21% (RR: 0.79, 95% CI: 0.64, 0.98). It also
significantly improved the hemoglobin levels (SMD:
0.98, 95% CI: 0.55-1.40) (Figure 3). MNPs did not show
a significant improvement in serum ferritin concentra-
tion and zinc deficiency.
For the anthropometric outcomes (Table 3), data was
pooled for six studies. MNPs did not show a significant
improvement in any of the anthropometric outcomes
including stunting (RR: 0.92, 95% CI: 0.81, 1.04), wasting
(RR: 1.13, 95% CI: 0.91, 1.40), underweight (RR:0.96,
95% CI: 0.83, 1.10), HAZ (SMD: 0.04, 95% CI: -0.13,
0.22), WAZ (SMD: 0.05, 95% CI: -0.12, 0.23) and WHZ
(SMD: 0.04, 95% CI: -0.13, 0.21), although showing
favorable trends, as the direction of effect was on the
positive side although non-significant.
For the morbidity outcomes (Table 3), data from four
studies was pooled. MNPs were associated with signifi-
cant increase in the incidence of diarrhea (RR: 1.04, 95%
CI: 1.01, 1.06) (Figure 4), while there was no significant
rise in recurrent diarrhea (RR: 2.86, 95% CI: 0.12-69.0),
fever (RR: 1.03, 95% CI: 0.70, 1.51) and URI (RR: 1.17,
95% CI: 0.71, 1.92).
Recommendation for the LiST model
Of the outcomes assessed for the effect of MNPs in chil-
dren, we applied the CHERG rules for evidence review
Figure 1 Search Flow Diagram
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to these outcomes. There was no data on mortality and
the evidence on anthropometric outcomes is weak. With
the current available evidence, we suggest that MNPs in
children is associated with a 34% decrease in the inci-
dence of anemia. The evidence of increased diarrhea
suggests careful evaluation of the associated risks.
Discussion
In this systematic review our objective was to summar-
ize the effect of MNPs on the health outcomes of
women and children. We did not find any study
reporting outcomes on women and seventeen studies
were included that reported on various outcomes on
children. The studies contributing data in this review
were conducted in developing countries hence increas-
ing the generalizability of the studies to children in
low and middle income countries with the highest
undernutrition rates. Most of the studies were effec-
tiveness trials evaluating the impact of MNPs in com-
munity settings. All of the studies were on children
Table 1 Characteristics of included studies
Study Country Target Group MNP Composition Duration
Adu-Afarwuah 2007 Ghana 6-12 month olds Β-Carotene-300 µg RE, Vitamin C-50 mg, Vitamin D3-7.5 µg, Folic acid-
150 µg, Iron (Fumarate)- 12.5 mg, Zinc (Gluconate)- 5 mg
1 year
Adu-Afarwuah 2008 Ghana 6-12 month olds Β-Carotene-300 µg RE, Vitamin C-50 mg, Vitamin D3- 7.5 µg, Folic acid-
150 µg, Iron (Fumarate)-12.5 mg, Zinc (Gluconate)- 5 mg
1 year
Agostoni 2007 Cambodia 6 month olds Fe- 12.5mg (fumarate), Zn- 5 mg (gluconate), Vitamin C - 50mg, Vitamin A -
300mg, Vitamin D3-7.5mg, Folic acid - 150mg, Potato maltodextrins SQ to 1 g.
1 year
Kounnavong 2011 Lao People’s
Democratic
Republic
6-52 month olds Vitamin A - 400μg RE, Vitamin D- 35 μg, Vitamin E - 5 mg TE, Vitamin B1, B2,
B6 - each 0.5 mg, Folic acid- 150 μg, Niacin- 6 mg, Vitamin B12- 0.9 μg,
Vitamin C- 30 mg, Iron- 10 mg, Zinc- 4.1 mg, Selenium- 17 μg,
Copper- 0.56 mg, Iodine- 90 μg
6 months
Kumar 2007 India 7-11 year olds Vitamin A 1500 IU/g, Vitamin B2, B6, B12 each -1 mg/g, Calcium pentothenate-
1 mg/g, Niacin -15 mg/g, Folic acid-100 mcg/g, Vitamin E -30 IU/g, Vitamin C-
30 mg/g, Iron - 10 mg/g, Lysine - 250 mg/g, Calcium - 15.63 %
1 year
Lundeen 2010 Kyrgyzistan 6-36 months old Elemental iron (fumarate)- 12.5 mg, Vitamin A - 300 μg, Zinc (gluconate)-
5 mg, Vitamin C (ascorbic acid) - 30 mg, Folic acid- 160 μg
2 months
Macharia-Mutie 2012 Kenya 1-5 year olds Retinyl palmitate - 100 mg RE, Cholecalciferol- 5 mg, 1-a tocopheryl acetate-
5 mg TE , Phylloquinone - 30 mg, Thiamin- 0.5 mg, Riboflavin - 0.5 mg,
Pyridoxine - 0.5 mg, Folic acid - 90 mg, Niacin - 6 mg, Vitamin B-12 - 0.9 mg,
Vitamin C - 60 mg, Iron (as NaFeEDTA) - 2.5 mg, Zinc - 2.5 mg, Selenium -
17 mg, Copper - 0.34 mg, Iodine- 30 mg
4 months
Menon 2007 Haiti 9-24 month olds Iron- 12.5 mg, Zinc- 5mg, Vitamin A- 400mg, Folic acid - 160mg,
Vitamin C- 30mg
2 months
Osei 2010 India 6-10 year olds Iron (NaFeEDTA)- 10 mg, Vitamin A (retinyl acetate)- 375 mg, Zinc (zinc
gluconate) -4.2 mg, Folic acid - 225 mg, Iodine (potassium iodide) - 90 mg,
Vitamin C (ascorbic acid) - 26.25 mg, Thiamine (thiamine mononitrate)- 0.68
mg, Riboflavin- 0.68 mg, Niacin (nicotinamide) - 9 mg, Vitamin B-12- 1.35 mg,
Vitamin B-6- 0.75 mg, Vitamin D (ergocalciferol) - 3.75 mg,
Vitamin E - 5.25 mg, Copper [CuSO4.(H2O)5]- 0.45 mg
8 months
Sharieff 2006 Pakistan 6-12 month olds Zinc gluconate- 5 mg, Ferrous fumarate - 30 mg, Vitamin C - 50 mg, Vitamin
A - 300 mg, Vitamin D3 - 7.5 mg, Folic acid- 150 mg
2 months
Varma 2007 India 36-66 month olds Ferrous fumarate- 14 mg, Vitamin A- 500 IU, Folic acid- 0.05 mg 6 months
Giovannini 2006 Cambodia 6 month olds Fe (iron II fumarate) - 12.5 mg, Zn (gluconate) - 5 mg, Vitamin C - 50 mg,
Vitamin A - 300 µg, Vitamin D3 - 7.5 µg, Folic acid 50- 150 µg, Potato
maltodextrins - SQ to 1 g
1 year
Sharieff 2007 China 3-6 years Iron (ferrous fumarate)- 30 mg, Zinc gluconate- 5mg, Vitamin C- 50 mg,
Vitamin A- 300 mg, Vitamin D3 - 7.5mg, Folic acid- 150mg
3 months
Suchdev 2010 Kenya 6-35 month olds Ferrous fumarate- 12.5mg, Vitamin A- 375 µg, Zinc- 5 mg, Folic acid- 150 µg,
Vitamin C-35 mg, Vitamin D3 - 5 µg, Vitamin E- 6 mg, Niacin- 6 mg, Copper-
0.6 mg, Iodine - 50 µg, Thiamine, riboflavin and vitamin B-6 - 0.5 mg, Vitamin
B-12- 0.9 mg
1 year
Jack 2012 Cambodia 6 month olds Iron (ferrous fumarate) - 12.5 mg, Zinc gluconate - 10 mg, Vitamin A - 300μg,
Iodine - 90 μg, Vitamin B1 - 0.5 mg, Vitamin B2 - 0.5 mg, Vitamin B6 - 0.5 mg,
Vitamin B12 - 0.9 μg, Niacin - 6 mg, Folate, folic acid - 160 μg, Vitamin C - 30
mg, Copper - 0.3 mg, Vitamin D - 5 μg, Vitamin E - 6 IU
18 months
Bhutta (unpublished) Pakistan 6-18 months Ferrous fumarate- 12.5 mg, Vitamin C - 50 mg, Vitamin A (retinol acetate)-
300 μg, Vitamin D - 5 μg, Folic acid - 150 μg, Zinc gluconate- 10 mg
24 months
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less than six years of age, except two studies [30,39]
that included children over 6 years of age although the
subgroup analysis for children under five did not show
any difference in the findings. Clinical heterogeneity
was observed due to variations in type of intervention
(number of micronutrients used ranged from 3 to
15), duration of the intervention (2-24 months),
target population and different time intervals for fol-
low-up. All the MNPs used contained iron in their
composition.
The intervention was mostly reported to be acceptable
by the mothers and children and there was no major
loss to follow-up reported due to the intervention in any
of the included studies. There have been no adverse
events identified by any study except one [38] that
reported increased diarrhea in the intervention group
compared to control.
This review shows that MNPs raise serum hemoglobin
levels and reduce anemia significantly, but the evidence on
growth is weak, as relatively few studies have evaluated
Table 2 Quality Assessment by Hematologic Outcome
Quality Assessment Summary of Findings
Directness No of events





Intervention Control RR / SMD
(95% CI)











The duration of the
studies ranged from 2-
12 months and the age
of the children from 6
months to 10 years.
1081 1443 RR: 0.66
[0.57, 0.77]













The duration of the
studies ranged from
2-12 months
404 986 RR: 0.43
[0.35, 0.52]

















4571 3783 SMD: 0.98
[0.55, 0.40]













761 788 SMD: -0.22
[-0.52, 0.09]












464 504 SMD: 1.66
[-1.60, 4.92]











duration from 6 months
to 12 months
850 884 SMD: 1.78
[-0.31, 3.88]
Zinc Deficiency: Moderate outcome specific quality of evidence












258 272 RR: 1.02
[0.87, 1.19]
Retinol Deficiency: Moderate outcome specific quality of evidence












111 145 RR: 0.79
[0.64, 0.98]
Salam et al. BMC Public Health 2013, 13(Suppl 3):S22
http://www.biomedcentral.com/1471-2458/13/S3/S22
Page 5 of 9
Table 3 Quality assessment by anthropometric and morbidity outcomes












810 838 RR: 0.92
[0.81, 1.04]












263 234 RR: 1.13
[0.91, 1.40]













All studies included more than 3
micronutrients. The studies ranged
in duration from 4-12 months.
671 679 RR: 0.96
[0.83, 1.10]
HAZ: Moderate outcome specific quality of evidence
Three RCT No significant
heterogeneity, fixed
effect model used





All studies included more than 3
micronutrients. The studies ranged
in duration from 6-12 months.
271 253 SMD: 0.04
[-0.13, 0.22]
WAZ: Moderate outcome specific quality of evidence
Three RCT No significant
heterogeneity, fixed
effect model used





All studies included more than 3
micronutrients. The studies ranged
in duration from 6-12 months.
271 253 SMD: 0.05
[-0.12, 0.23]
WHZ: Moderate outcome specific quality of evidence
Three RCT No significant
heterogeneity, fixed
effect model used





All studies included more than 3
micronutrients. The studies ranged
in duration from 6-12 months.
271 253 SMD: 0.04
[-0.13, 0.21]














Number of micronutrients ranged
from 5-15. Duration varied from 2-12
months. One of the studies targeted
children in school.
1692 1679 RR: 1.04
[1.01, 1.06]
Recurrent Diarrhea: Moderate outcome specific quality of evidence
One RCT Only one study Study was
conducted in
Cambodia
Study was conducted over a 12
month period
1 0 RR: 2.86
[0.12,
69.00]
URI: Moderate outcome specific quality of evidence
Two RCT No significant
heterogeneity, fixed
effect model used





Number of micronutrients ranged
from 5-14. Duration varied from 8-12
months. One of the studies targeted
children in school.
30 26 RR: 1.17
[0.71, 1.92]
Fever: Moderate outcome specific quality of evidence
One RCT Only one study Study was
conducted in
India
41 41 RR: 1.03
[0.70, 1.51]
Figure 2 Forest Plot for the impact of MNPs on anemia in children
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this outcome. Improved hemoglobin and anemia status
could be attributable to the iron component in all the
MNPs used. Some studies have reported benefits on other
developmental outcomes like walking by 12 months but
not on growth [22]. This could be due to relatively shorter
duration of the intervention to show actual long term
impacts. These findings also suggest that multiple micro-
nutrient interventions alone might not improve growth
outcomes. To ensure long term impacts and sustainability,
health education that aims to modify food habits would be
necessary to improve child growth rates. Also, if the inter-
vention initiation coincides with the child’s diet transition
from breast feeding to complementary feeding, the results
may show improved growth.
The finding of significantly increased diarrhea is
potentially alarming. It is mainly based on the significant
increase in diarrhea observed in one large trial [38]. The
association between increased diarrhea with iron supple-
mentation is well recognized in the literature and is also
reported in a review on iron supplementation by Gera
[40]. However, our finding of excess morbidity and
negligible growth benefit cannot be ignored in settings
where large scale use of MNPs is being considered. The
increased diarrhea burden could be one of the potential
explanations for reduced growth benefits of MNPs.
The evidence is weak for any effect of MNPs on
growth, as there were very few studies pooled for each
outcome. More research is needed and studies need to
report the outcomes of stunting, wasting, morbidity and
mortality consistently to strengthen the evidence and
evaluate its actual impact on growth and morbidity. A
major research gap identified was that there were no
studies evaluating the impact on women as all the stu-
dies targeted children only.
Conclusion
Our analysis of the effect of MNPs in children suggests
benefit in improving anemia and hemoglobin however
there is lack of impact on growth. Evidence of
increased diarrhea requires careful consideration before
recommending the intervention for implementation at
scale.
Figure 3 Forest Plot for the impact of MNPs on hemoglobin in children
Figure 4 Forest Plot for the impact of MNPs on diarrhea in children
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